Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).
Peter C. Black(University of British Columbia), Ian M. Thompson(The University of Texas at San Antonio Health Science Center), Wassim Kassouf(McGill University), Catherine M. Tangen(American Urological Association), Vadim S. Koshkin(UCSF Helen Diller Family Comprehensive Cancer Center), Melissa Plets(Cancer Research And Biostatistics), Sima P. Porten(City College of San Francisco), Seth P. Lerner(Baylor College of Medicine), Elad Sharon(National Cancer Institute), David J. McConkey(Johns Hopkins University), Richard Carlton Bangs(SWOG Cancer Research Network), Kelly Stratton(Oklahoma City University), Parminder Singh(WinnMed), Trinity J. Bivalacqua(University of Pennsylvania), Scott Lucia(University of Colorado Anschutz Medical Campus), William T. Lowrance(University of Utah)
Cited by 55
Related Papers
Frailty in Older Adults: Evidence for a Phenotype
|The Journals of Gerontology Series A|2001|24.4k
Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress
|New England Journal of Medicine|2005|3.1k
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
|New England Journal of Medicine|2003|2.6k